Oct 31 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PROVIDES POSITIVE INTERIM UPDATE FROM PHASE 2B TRIAL OF MDNA55 IN RECURRENT GLIOBLASTOMA
* MEDICENNA - PROMISING INTERIM EFFICACY, SAFETY RESULTS FROM PATIENTS TREATED AT LOW DOSES IN ON-GOING PHASE 2B CLINICAL TRIAL OF MDNA55
* MEDICENNA - REVIEW OF SAFETY DATA TO DATE INCLUDING HIGH DOSE COHORTS SHOWED THAT SAFETY PROFILE OF MDNA55 WAS UNCHANGED FROM PREVIOUS STUDIES